Navigation Links
DelMar Pharmaceuticals Announces Acquisition and $5.4 Million Private Placement to Advance Novel Cancer Therapies
Date:1/25/2013

>. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.

For further information, please visit www.delmarpharma.com
or contact Jeffrey A. Bacha , President & CEO  (604) 629-5989

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.


'/>"/>
SOURCE DelMar Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)...  CytRx Corporation (NASDAQ: CYTR ), a ... today announced positive updated results from its ongoing ... treatment of unresectable glioblastoma multiforme (GBM), a deadly ... is designed to investigate the preliminary efficacy and ... progressed following prior treatment with surgery, radiation and ...
(Date:5/21/2015)... , May 21, 2015 /PRNewswire/ - RepliCel ... clinical stage regenerative medicine company focused on the ... upcoming poster presentation at the International Society for ... for chronic Achilles tendinosis currently in a Phase ... May 29 th from 5:30 PM to ...
(Date:5/20/2015)... , May 20, 2015 ... presented preliminary data demonstrating the ability of the ... fibrosis (IPF) from other interstitial lung diseases (ILDs) ... the classifier,s potential to help thousands of patients ... ambiguity in IPF diagnosis – a frequent challenge ...
(Date:5/20/2015)... May 19, 2015 Research and Markets ... "Global Cell Therapy Market Outlook 2020 " ... therapy in tissue and regenerative medicine is expected to ... options which could help in the growth of deregulated ... but they are unable to form new tissue or ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3
... Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var ...
... Nov. 16, 2010 AVANIR Pharmaceuticals, Inc. ... intends to offer and sell shares of its common stock ... acting as sole book-running manager in the offering and Canaccord ... and Merriman Capital are acting as co-managers for the offering. ...
... ORLEANS, and RESEARCH TRIANGLE PARK, N.C., Nov. 16, ... in vitro data demonstrating that the ... substrates for the human Organic Anion Transporters (hOATs) ... nephrotoxicity via this mechanism.  These data, presented at ...
Cached Biology Technology:Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany 2Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany 3Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany 4Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany 5Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany 6Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany 7Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany 8Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany 9AVANIR Pharmaceuticals Announces Proposed Public Offering of Common Stock 2Chimerix's PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157 2Chimerix's PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157 3Chimerix's PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157 4
(Date:5/14/2015)... 14, 2015 Research and Markets ( ... "Fingerprint Sensors Market in Smart Mobile Devices " ... that 2014 was a watershed year for fingerprint sensors ... ,Apple Pay,. Apple gave fingerprint sensors a raison d,etre ... Fingerprint sensors are a must-have feature in flagship smartphones. ...
(Date:5/11/2015)... , May 11, 2015  Through a well-rounded UAS ... had a strong showing at AUVSI,s Unmanned 2015 ... representatives of Ohio,s UAS industry met ... abroad from all points along the UAS ecosystem. ... Coalition,s (DDC) Vice President for Aerospace Rich Knoll . ...
(Date:5/8/2015)... JOSE, Calif. , May 8, 2015 Synaptics ... interface solutions, today announced that members of the executive management ... J.P. Morgan 43rd Annual Technology, Media and Telecom Conference ... Waterfront Hotel in Boston, MA ... May 27, 2015 Time: 2:45pm ET Location: The New York ...
Breaking Biology News(10 mins):Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Synaptics to Present at Upcoming Investor Conferences 2
... far the most successful life form on Earth. As ... spaceflight, they don,t do too badly in microgravity either. ... cosmonauts who were stricken with infections during their flights. ... treatments against most harmful bacteria. But previous studies have ...
... to choose healthy options at the grocery store if they ... as a motivational tool, according to new research published in ... Psychological Science. The research adds to a body of ... increasing healthy behaviors, a growing concern for many different groups, ...
... and was approved for the treatment of neuropathic pain ... However, little evidence is available on the effects and ... period. A recent study by Yanbo Zhang and colleague ... that excitatory amino acids and protein kinase C are ...
Cached Biology News:Beating bacteria on Earth -- and in space 2Beating bacteria on Earth -- and in space 3Beating bacteria on Earth -- and in space 4Laying money on the line leads to healthier food choices over time 2Laying money on the line leads to healthier food choices over time 3
Lyophilized. Purity: ≥90% by electrophoresis. Reconstitute in 0.3% NaCl. Prepared from serum that has been shown by certified tests to be negative for HBsAg and for HIV and HCV antibodies. ...
PP2B-Abeta (C-20)...
Goat polyclonal to Duffy / FY / DARC...
... Description: Proteinase K is a highly active and ... applications purified from the fungus T. album. It ... of N-substituted hydrophobic aliphatic and aromatic amino acids ... protease. Proteinase K is useful in purifying high ...
Biology Products: